Main Article Content

Abstract

BACKGROUND


Alopecia areata (AA) is a common, chronic, autoimmune, inflammatory disease that causes non scarring hair loss. Treatment of moderate to severe AA is challenging without a definitive cure. This study was undertaken to compare the efficacy of platelet rich plasma (PRP) - a novel procedural therapy, intralesional triamcinolone acetonide (ILS) and intralesional normal saline (NS) in moderate to severe AA.


METHODS


A total of 75 patients clinically diagnosed with Alopecia Areata were enrolled and the severity of the disease was assessed by SALT score. Twenty-five patients each in Group A, B and C were treated with PRP, ILS and NS respectively at monthly intervals for four sessions. Improvement in hair regrowth (based on reduction in SALT SCORE) and adverse effects were noted in all cases in each group at each session and one month after the final sitting. Statistical analysis was done using the student's t-test for quantitative values and the chi-square test for qualitative values.


RESULTS


Males outnumbered females with a percentage of 74.7, whereas females were 25.3 %. Male: female ratio of 2.9:1. Patchy type of AA was the most common clinical type observed (54.66 %), followed by sub totalis (14.66 %). Forty-eight cases (64 %) had a severity grade of S2 (26-50) followed by twenty-three cases (30 %) grade of S3 (51-75). After 20 weeks of treatment, the mean percentage of SALT score improvement with the highest efficacy was seen in the ILS group (63.15 %) followed by the PRP group (37.51 %). Improvement of hair regrowth with the excellent response (66 %) was achieved in ILS followed by 33 % in the PRP group, comparatively rapid reduction in SALT SCORE within four weeks was observed in the ILS group whereas gradual reduction in SALT SCORE was achieved in 8-12 weeks in PRP group. Relapse was seen in 21.7 % of patients in the ILS group and 1 (4.1 %) patient in the PRP group in the follow-up period of four months. No major adverse effects were seen in any of the groups.


CONCLUSIONS


Efficacy of ILS was more significant than PRP and Placebo but with a higher recurrence rate. Both treatments were extremely safe, with no significant adverse effects.

Keywords

ILS, PRP, SALT Score, Triamcinolone Acetonide.

Article Details

How to Cite
M. Jaya Kumar, P.V. Krishnam Raju, B. Gayatri Devi, K.V.T. Gopal, & T. Narayana Rao. (2022). Randomized Study to Evaluate the Efficacy of Platelet Rich Plasma, Intralesional Triamcinolone Acetonide and Intralesional Normal Saline in Moderate to Severe Alopecia Areata. Journal of Evolution of Medical and Dental Sciences, 11(5), 546–550. https://doi.org/10.14260/jemds/2022/110

References

  1. Wasserman D, Guzman-Sanchez DA, Scott K, et al. Alopecia areata. Int J Dermatol 2007;46(2):121-31.
  2. Seetharam KA. Alopecia areata: an update. Indian J Dermatol Venereol Leprol 2013;79(5):563-75.
  3. Gupta MA, Gupta AK, Watteel GN. Stress and alopecia areata: a psycho dermatologic study. Acta Derm Venereol 1997;77(4):296-8.
  4. Barahmani N, Sehabath MB, Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol 2009;61(4):581-91.
  5. Trink A, Sorbellini E, Bezzola P, et al. A randomized, double-blind, placebo-and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol 2013;169(3):690-4.
  6. Papadopoulos AJ, Schwartz RA, Janninger CK. Alopecia areata: pathogenesis diagnosis, and therapy. Am J Clin Dermatol 2003;1(2):101-5.
  7. Thomas EA, Kadyan RS. Alopecia areata and autoimmunity: a clinical study. Indian J Dermatol 2008;53(2):70-4.
  8. Mishra A, Sharma RL. A study of clinical profile of Alopecia areata in a tertiary care hospital in Western Odisha. IAIM 2017;4(5):26-30.
  9. Hegde SP, Naveen KN, Athanikar SB, et al. Clinical and dermatoscopic patterns of alopecia areata: a tertiary care centre experience. Int J Trichology 2013;5(3):132-6.
  10. Al-Mutairi N, Eldin ON. Clinical profile and impact on quality of life: seven years experience with patients of alopecia areata. Indian J Dermatol Venereol Leprol 2011;77(4):489-93.
  11. Kaur S, Mahajan BB, Mahajan R. Comparative evaluation of intralesional triamcinolone acetonide injection, narrow band Ultraviolet B, and their combination in Alopecia Areata. Int J Trichol 2015;7(4):148-55.
  12. Rehman F, Dogra N, Wani MA. Serum Vitamin D levels and alopecia areata- a hospital based case- control study from North- India. Int J Trichology 2019;11(2):49-57.
  13. Ranpariya RH, Gupta SB. Intralesional triamcinolone acetonide versus platelet rich plasma: a comparative study in the treatment of alopecia areata of scalp. Int J Res Dermatol 2019;5(3):521-7.
  14. Kumar A, Sharma RP, Bali S, et al. Role of platelet rich plasma therapy in alopecia areata- a prospective study. IJCMR 2016;3:2499-502.
  15. Shumez H, Prasad PVS. Intralesional platelet rich plasma vs intralesional triamcinolone in the treatment of alopecia areata: a comparative study. Int J Med Res Health Sci 2015;4(1):118-22.
  16. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000;42(4):549-66.
  17. Kumaresan M. Intralesional steroids for alopecia areata. Int J Trichology 2010;2(1):63-5.
  18. Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol 2009;8(10):909-12.
  19. Ninama K, Mahajan R, Bilimoria F, et al. A clinical study on alopecia areata. Int J Res Dermatol 2018;4(1):66-71.
  20. Singh S. Role of platelet-rich plasma in chronic alopecia areata: our centre experience. Indian J Plast Surg 2015;48(1):57-9.

Most read articles by the same author(s)